Verzenios ® ▼ (abemaciclib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Verzenios Summary of Product Characteristics (SmPC)

What is Verzenios® ▼ (abemaciclib) recommended dosing and administration in patients with metastatic breast cancer?

The recommended dose of abemaciclib is 150 mg twice daily in combination with endocrine therapy.

UK_cFAQ_ABE027_DOSING_ADMINISTRATION
UK_cFAQ_ABE027_DOSING_ADMINISTRATION
en-GB

How Long Should Patients take Abemaciclib? 

Patients should take abemaciclib without a treatment pause, as long as they benefit from the therapy or until unacceptable toxicity occurs.1

How Is Abemaciclib Administered?

Patients should

  • take abemaciclib with or without food
  • avoid grapefruit or grapefruit juice
  • take the doses at the same times every day, and
  • swallow the tablet whole.1

When is Abemaciclib Dose Modification Necessary?

Dose modification is recommended based on individual safety and tolerability.

The management of adverse reactions, such as diarrhea, hematologic toxicities, hepatotoxicity, or pneumonitis, may require dose interruption, dose reduction, or both.2 

Please find detailed information in the Verzenios Summary of Product Characteristics.1 

How is an Abemaciclib Overdose Managed?

There is no known antidote for an abemaciclib overdose.2Patients may develop fatigue and diarrhoea. Provide general supportive care.1

Are Dose Modifications Necessary for Patients with Hepatic Impairment

Dose adjustments are only required for patients with severe hepatic impairment (Child-Pugh C). Decrease the dosing frequency to once daily in these patients. 

No dose adjustments are necessary for patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment.1 

Are Dose Modifications Necessary for Patients with Renal Impairment?

No dose adjustment is required for patients with mild or moderate renal impairment. We have no data in patients with severe impairment or on dialysis.

References

1Verzenios [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: July 28, 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request